Renal · Electrolyte Disorders
The facts most likely to be tested
The most common cause of hypermagnesemia is renal insufficiency or chronic kidney disease in the setting of magnesium-containing medication intake.
Early clinical manifestations include loss of deep tendon reflexes (DTRs), which typically occurs when serum magnesium levels exceed 4-5 mEq/L.
Severe hypermagnesemia presents with respiratory depression, hypotension, and bradyarrhythmias due to the inhibition of calcium influx at the neuromuscular junction.
Electrocardiogram findings in hypermagnesemia mimic hyperkalemia, specifically showing prolonged PR interval, widened QRS complex, and peaked T waves.
The first-line treatment for symptomatic hypermagnesemia is intravenous calcium gluconate to antagonize the membrane effects of magnesium.
For patients with intact renal function, intravenous fluids and loop diuretics (e.g., furosemide) are used to promote renal magnesium excretion.
Patients with severe, symptomatic hypermagnesemia and renal failure require hemodialysis as the definitive treatment to clear excess magnesium.
Vignette unlocked
A 68-year-old male with a history of stage 4 chronic kidney disease presents to the emergency department with progressive muscle weakness and lethargy. He reports recent self-medication with over-the-counter magnesium-containing antacids for dyspepsia. On physical examination, he is hypotensive with a blood pressure of 90/60 mmHg and has absent deep tendon reflexes in the lower extremities. An ECG reveals a widened QRS complex and a prolonged PR interval. His serum magnesium level is 8.5 mg/dL.
What is the most appropriate initial pharmacologic intervention?
Intravenous calcium gluconate
The patient is exhibiting signs of severe hypermagnesemia (absent DTRs, ECG changes); IV calcium gluconate is the immediate treatment to stabilize the cardiac membrane and antagonize the neuromuscular effects of magnesium.
Full handout
High yield triage
Etiology / Epidemiology
Almost exclusively occurs in patients with renal insufficiency (GFR <30 mL/min) receiving magnesium-containing medications.
Clinical Manifestations
Progressive loss of deep tendon reflexes (DTRs), areflexia, and respiratory depression.
Diagnosis
Serum magnesium level >2.6 mg/dL is diagnostic; serum magnesium is the gold standard.
Treatment
Stop all magnesium sources; IV calcium gluconate for cardiac stabilization; furosemide for excretion.
Prognosis
Severe cases lead to cardiac arrest; mortality is high if not recognized before respiratory paralysis.
Full handout
Epidemiology & Etiology
Hypermagnesemia is rare in patients with normal renal function due to the kidney's high capacity for excretion. It is most commonly iatrogenic, seen in patients with chronic kidney disease (CKD) treated with magnesium-containing antacids, laxatives, or therapeutic magnesium sulfate for eclampsia.
Pertinent Anatomy
The kidneys are the primary site of magnesium homeostasis, reabsorbing 95% of filtered magnesium in the loop of Henle and distal tubule. Impairment of this excretory pathway is the prerequisite for clinical toxicity.
Pathophysiology
Magnesium acts as a physiological calcium antagonist, inhibiting the release of acetylcholine at the neuromuscular junction. Elevated levels cause progressive neuromuscular blockade, leading to muscle weakness and eventual paralysis. Cardiac effects include slowed conduction, resulting in prolonged PR interval and QRS widening.
Clinical Manifestations
Early symptoms include nausea, flushing, and hypotension. As levels rise, patients exhibit diminished DTRs, which is the most reliable clinical sign of toxicity. Respiratory depression and complete heart block are life-threatening emergencies that occur at higher concentrations.
Diagnosis
The diagnosis is confirmed via serum magnesium levels. Levels >2.6 mg/dL are abnormal, while levels >5.0 mg/dL typically manifest clinical symptoms. An ECG should be performed to assess for conduction delays.
Treatment
The first step is to discontinue all magnesium intake. For symptomatic patients, IV calcium gluconate is the first-line treatment to antagonize membrane effects. If renal function is preserved, furosemide promotes excretion; otherwise, hemodialysis is required for severe, refractory cases.
Prognosis
Prognosis is excellent if identified early and magnesium sources are removed. Cardiac arrest is the primary cause of mortality in untreated cases; continuous cardiac monitoring is mandatory until levels normalize.
Differential Diagnosis
Hyperkalemia: presents with peaked T-waves rather than loss of DTRs
Hypercalcemia: presents with shortened QT interval and polyuria
Myasthenia Gravis: presents with ptosis and fatigable weakness
Guillain-Barre Syndrome: presents with ascending paralysis and albuminocytologic dissociation
Botulism: presents with descending paralysis and cranial nerve involvement